IRF3 and fatty liver disease: For example, both FGF21 and AKT1S1 (also known as PRAS40) are substrates for phosphorylation by AKT kinase [59, 60], and effect fatty liver disease, while IRF3 mediates HFD-induced insulin resistance and impaired hepatic glucose metabolism trough a mechanism involving AKT [61].